Changes in Hong Kong stocks | Goli Pharmaceutical-B (01672) achieved positive top-line results in the 13-week phase II study on treating obesity with nearly 15% ASC30

The Zhitong Finance App learned that Goli Pharmaceutical-B (01672) was nearly 15% higher. As of press release, it had risen 14.93% to HK$16.47, with a turnover of HK$10.784 million.

According to the news, Goli Pharmaceuticals announced that the 13-week phase II study (NCT07002905) evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, has achieved positive top-line results. In addition to achieving statistically significant and clinically significant weight loss, ASC30 also reached a secondary and exploratory endpoint. ASC30 reduced several known cardiovascular risk markers in all dosage groups, including total cholesterol, low density lipoprotein cholesterol (LDL-C), triglycerides, and systolic and diastolic blood pressure. In the steady-state, blood concentrations of ASC30 increase with increasing dose.